Table 1.

Studies evaluating the efficacy of anti-TNF agents for the prevention of endoscopic postoperative recurrence in Crohn’s disease

Year	Author	Anti-TNF	Control group	Endoscopic postoperative recurrence with anti-TNF n/N (%)
2006	Sorrentino [37]	Infliximab	Mesalamine	0/1 (0%)
2007	Sorrentino [38]	Infliximab	Mesalamine	0/7 (0%)
2009	Regueiro [39]	Infliximab	None	1/11 (9%)
2010	Sorrentino [40]	Infliximab	None	0/12 (0%)
2012	Yoshida [41]	Infliximab	None	3/14 (21%)
2012	Aguas [42]	Adalimumab	None	6/29 (21%)
2012	Papamichael [43]	Adalimumab	None	1/8 (12%)
2012	Sakuraba [44]	Infliximab	None	6/10 (60%)
2012	Savarino [45]	Adalimumab	None	0/6 (0%)
2013	Savarino [47]	Adalimumab	Mesalamine Thiopurines	0/16 (0%)
2013	Armuzzi [48]	Infliximab	Thiopurines	1/11 (9.1%)
2014	Tursi [49]	Infliximab Adalimumab	None	3/20 (15%) Infliximab: 2/10 (20%) Adalimumab: 1/10 (10%)
2015	De Cruz [50]	Adalimumab	Thiopurines	6/28 (21%)
2015	Kotze [51]	Infliximab Adalimumab	Mesalamine Thiopurines	25/96 (26%) Infliximab 16/59 (27%) Adalimumab 9/37 (24%)
2016	Regueiro [52]	Infliximab	None	17/147 (12%)
2016	Preda [53]	Infliximab Adalimumab	None	8/26 (31%) Infliximab 4/14 (29%) Adalimumab 4/12 (33%)
2016	Takeshima [54]	Adalimumab	None	5/14 (36%)
2017	Collins [55]	Infliximab Adalimumab Certolizumab	None	10/39 (24%)
2017	López–Sanromán [56]	Adalimumab	Thiopurines	19/45 (42%)
2017	Allocca [57]	Infliximab Adalimumab	Mesalamine Thiopurines	12/44 (27%)
2017	Fay [58]	Infliximab Adalimumab	None	26/73 (36%) Infliximab 14/32 (44%) Adalimumab 12/41 (29%)
2018	Asada [59]	Adalimumab	None	9/26 (35%)
2018	Fukushima [60]	Infliximab	Mesalamine	4/19 (21%)
2018	Auzolle [61]	Infliximab Adalimumab	None	26/66 (39%)
2018	Hiraoka [62]	Infliximab Adalimumab	None	17/36 (47%) Infliximab 13/27 (48%) Adalimumab 4/9 (44%)
2018	Yamada [63]	Infliximab Adalimumab	Thiopurines Vedolizumab	13/38 (34%)
2019	Cañete [64]	Infliximab Adalimumab	None	52/152 (34%) Infliximab 22/55 (40%) Adalimumab 29/97 (30%)
2019	Maggiori [65]	Infliximab Adalimumab	Thiopurines	32/93 (34%)
2021	Rivière [66]	Anti–TNF	Thiopurines	3/18 (17%)
2022	Yanai [67]	Infliximab Adalimumab	Vedolizumab Ustekinumab	90/224 (40%)
2022	Le Cosquer [68]	Infliximab Adalimumab	Thiopurines Vedolizumab Ustekinumab	13/61 (21%)
2022	Buisson [69]	Infliximab Adalimumab	Mesalamine Thiopurines	45/184 (30%)
2022	Yu [70]	Infliximab Adalimumab	None	13/31 (42%)
2022	Buisson [71]	Infliximab Adalimumab	Ustekinumab	16/35 (46%)
2022	Axelrad [72]	Infliximab Adalimumab	Vedolizumab Ustekinumab	61/223 (27%

Endoscopic postoperative recurrence: Rutgeerts ≥ i2 at 6–12 months, except in these studies: Fay [58] (median 15 months); Cañete [64] (18 months); Sakuraba [44] (24 months); Takeshima [54] (median 25 months)